AccuMetab™ Human CYP3A5 Enzyme, Catalytically Active

CAT#: ITS-0426-YL7
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP3A5 for accurate Phase I drug metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Highly homologous to CYP3A4, CYP3A5 shares overlapping substrate specificities but exhibits a distinct polymorphic expression pattern across different ethnic populations. Including this isoform in in vitro studies ensures a comprehensive understanding of total CYP3A-mediated clearance and patient-specific drug exposure risks.
Key Features
Proprietary E. coli expression; High and low reductase ratio options; Key polymorphic contributor to overall CYP3A clearance; Validated for tacrolimus and immunosuppressant metabolism
Applications
Drug Metabolism Studies, Reaction Phenotyping, DDI Assessment, Metabolite ID
Research Areas
ADME; Drug-Drug Interactions (DDI); Toxicology
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry